TRASTUZUMAB
ER Positive, HER2 Positive Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang Universitymonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the ER Positive, HER2 Positive Breast Cancer cohort.
Same molecule, other indications
TRASTUZUMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →